respondent
whereby the respondent was granted right to use "Monsanto Technology"
::: Uploaded on - 06/03/2019 ::: Downloaded on - 14/03/2019 ... respondent produced and sold in the market
genetically modified hybrid cotton seeds, using the said technology. Sales
reports qua such sales were also issued
rapid evolution in business resultant upon the swift changes of
technology in modern times. The Court cautioned against placing the
discourse on Section ... business founded on software, bio-
genetics or a business at the cutting edge of technology. The
interpretation of Section 2(s) must be such
basis to use, test, produce and sell genetically modified
hybrid cotton planting seeds. In return for this technology,
Monsanto India receives trait fees based ... Committee of the Department of
Biotechnology, Ministry of Science and Technology, Ministry of
Environment, Genetic Engineering Advisory Committee (GEAC)
and others responsible. These approvals need
Authority as detailed in paragraph 22.7.4(i);
(vi) Genetically engineered drugs produced by recombinant DNA technology and specific cell/tissue targeted drug formulations will
basis to use, test, produce and sell genetically modified
hybrid cotton planting seeds. In return for this technology,
Monsanto India receives trait fees based ... Committee of the Department of
Biotechnology, Ministry of Science and Technology, Ministry of
Environment, Genetic Engineering Advisory Committee (GEAC)
and others responsible. These approvals need
manufacturing highly specialized lifesaving biologicals like vaccines using
cutting edge genetic and cell-based technologies, antisera and other
medical specialties. The Plaintiff
manufacturing highly specialized lifesaving biologicals like vaccines using
cutting edge genetic and cell-based technologies, antisera and other
medical specialties. The Plaintiff
manufacturing highly specialized lifesaving biologicals like vaccines using
cutting edge genetic and cell-based technologies, antisera and other
medical specialties. The Plaintiff
manufacturing highly specialized lifesaving biologicals like vaccines using
cutting edge genetic and cell-based technologies, antisera and other
medical specialties. The Plaintiff
supra) in Paragraph No.25 has taken note of swift evolution of
technology which led to a change in business environment in the following
words ... business founded on software, bio-genetics or a
business at the cutting edge of technology. The interpretation
of Section 2(s) must be such
